What were the primary drivers of Stryker's sales growth in the first quarter of 2001?

Stryker's net sales increased by 13% to $634.2 million. This growth was primarily driven by a 12% increase in unit volume, a 2% increase in selling prices, and contributions from acquired businesses. Domestic sales saw a strong 19% increase, while international sales grew 3% (11% excluding unfavorable foreign currency impacts). Both the Orthopaedic Implants and MedSurg Equipment segments reported solid sales increases.

How did Stryker's profitability perform in the first quarter of 2001?

Profitability improved significantly. Net earnings increased by 24% to $64.1 million, leading to a 22% rise in basic EPS to $0.33 and a 23% rise in diluted EPS to $0.32. Gross profit margin remained strong at 63.4%. The effective tax rate also decreased to 33.0% from 34.0% in the prior year, contributing to the net earnings growth.

What is the company's current financial health and liquidity position?

Stryker maintained a healthy financial position. Working capital increased to $415.1 million, supported by improved asset management. The company generated $74.6 million in operating cash flow and ended the quarter with $61.1 million in cash. Despite substantial long-term debt of $960.1 million, management expressed confidence in their ability to meet future obligations through existing cash, anticipated operating cash flows, and available borrowing capacity under their credit facilities.

Are there any significant new accounting standards adopted or impacting the financial statements?

Yes, effective January 1, 2001, Stryker adopted FASB Statement No. 133 regarding derivative instruments and hedging activities. This led to the recognition of derivatives on the balance sheet at fair value and a cumulative effect adjustment of $3.5 million recorded in accumulated other comprehensive gain (loss) related to interest rate swap agreements. The company also uses foreign currency forward contracts and cross-currency swaps to manage currency risks.

SYK 10-Q Quarterly Report Q1 FY2001 — Revenue, Net Income, EPS

Summary

Stryker Corporation's first quarter of 2001 demonstrates robust top-line growth with a 13% increase in net sales to $634.2 million, driven by strong performance in both its Orthopaedic Implants and MedSurg Equipment segments. This growth was fueled by increased unit volumes and slightly higher selling prices, though partially offset by unfavorable foreign currency exchange rates. The company also saw a significant 24% rise in net earnings to $64.1 million, resulting in improved basic and diluted earnings per share of $0.33 and $0.32, respectively. Management highlights improved asset management, with decreased days sales outstanding for accounts receivable and inventory, contributing to a healthier working capital position. Financially, Stryker maintained a strong liquidity position, generating substantial cash from operations and ending the quarter with $61.1 million in cash. Despite managing $960.1 million in long-term debt, the company believes its current cash flows and available credit facilities are sufficient to meet future obligations, including debt repayments and working capital needs. Investments in research and development have increased as a percentage of sales, signaling a commitment to innovation with new product introductions.

Key Highlights

1Net sales increased 13% to $634.2 million in Q1 2001 compared to Q1 2000.
2Net earnings grew by 24% to $64.1 million, with EPS rising to $0.33 (basic) and $0.32 (diluted).
3Orthopaedic Implants sales rose 7% (12% excluding FX), and MedSurg Equipment sales increased 19% (21% excluding FX).
4The company generated $74.6 million in cash from operating activities, a significant increase from $28.3 million in the prior year.
5Working capital improved, with accounts receivable days sales outstanding decreasing by 4 days and days sales in inventory by 5 days.
6Research, development, and engineering expenses increased 24% and represented 5.6% of sales, up from 5.1% in the prior year.

STRYKER CORP Quarterly Report for Q1 Ended Mar 31, 2001

Summary

Key Highlights

Frequently Asked Questions